Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Immune Checkpoint Inhibition × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 6 Esophageal Neoplasms 3 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Advanced Gastric Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Pancreatic Neoplasms 1 Liver Neoplasms 1 Liver Diseases 1 Leukemia, Myeloid, Acute 1 Immune Checkpoint Inhibition 1 ESCC 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Bites and Stings 1

Interventions

camrelizumab 1 apatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04507750 2020-09-21

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Qianfoshan Hospital

Phase NA Unknown

Immune Checkpoint Inhibition

Data powered by HemOnc (CC BY 4.0) Colophon ⚡